Stein Gold, who previously touched on these findings in an HCPLive interview, was asked in this video about what stood out in the panel discussion about improving early recognition of psoriatic arthritis (PsA). “When we think about our psoriasis patients, we have to remember that this is a systemic disease, and psoriatic arthritis is one of those manifestations that occurs quite commonly in our psoriasis patients,” Stein Gold explained. Stein Gold noted during certain times, clinicians should have the potential for PsA development at front of mind. Later, Stein Gold was asked about practicing clinicians trying to navigate an increasingly complex therapeutic landscape. Disclosures: Stein Gold has reported serving as an investigator, advisor, or speaker for AbbVie, Amgen, Arctis, Bristol Myers Squibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB.